House Bill Could Help Employers Dodge GINA

HR 1313 could circumvent protections offered by the Genetic Information Nondiscrimination Act, enabling employers to incentivize employee sharing of genetic and other medical information.

Written byJoshua A. Krisch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

i124NEWS.TVThe Genetic Information Nondiscrimination Act (GINA) prohibits US employers and health insurance companies from making decisions based on the results of genetic screenings, with several exceptions. If employees voluntarily submit their genetic information as part of a workplace wellness program, for instance, they are not protected by GINA. But employers must not coerce workers into doing so.

Now, House Republicans have approved HR 1313, a bill that, if enacted, would remove at least one of GINA’s protections: essentially, it would allow employers to pressure workers into submitting their genetic information to the company in exchange for up to 30 percent reductions in health insurance costs. Once employees have submitted their information (voluntarily, as part of a workplace wellness program), few of GINA’s protections would apply.

“What this bill would do is completely take away the protections of existing laws,” Jennifer Mathis of the Bazelon Center for Mental Health Law told STAT News. GINA and similar legislation “would be pretty much eviscerated,” she added.

The American Academy of Pediatrics and nearly 70 other organizations have drafted a letter opposing the bill, which has ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies